Multiple Sclerosis

Improving cognitive assessment with higher fidelity measures.

Cognitive impairment affects 50-70% of Multiple Sclerosis (MS) patients and is noted as one of the most disabling aspects of the disease. Worsening cognitive processing speed impacts patients’ quality of life as simple tasks become more difficult.

Addressing cognitive impairment and decline is vital in the development of MS treatments. Cogstate supports sponsors in these efforts by providing highly sensitive and reliable computerized cognitive testing, as well as support for conventional assessments, such as the BICAMS, MSFC, and PASAT.

Talk with our Team About Your Study

Optimize Clinical Outcome Assessment in Multiple Sclerosis Clinical Trials

Cogstate’s team of scientific and operational experts deliver innovative technology, proven operational delivery models, and leading scientific support for both digital and conventional clinical outcome assessments in MS trials.

Guidance to Select Validated, Fit-For-Purpose Tools to Collect Outcomes Relevant to Cognitive Impairment in MS

Choosing appropriate endpoints and designing strategic protocols are important decisions in the planning phase that impact future study results. Cogstate’s team of scientists have the expertise to advise your team on vital study considerations, help you answer key drug development questions, and design trials with reduced risk and uncertainty.

Leverage Sensitive and Reliable Computerized Cognitive Batteries

Cogstate’s computerized batteries of highly sensitive tests provide rapid and reliable measurement of distinct cognitive domains affected by MS such as processing speed and attention. Tests can be grouped into customizable batteries for a complete and nuanced picture of a subject’s cognitive state. Cogstate tests are culture- and education-neutral and designed for repeated administration with minimal practice or learning effects, making them ideal for use in global clinical trials. Tests have high patient acceptability and reduce burden on patient and sites.

Implement Robust Data Quality Programs for Conventional Assessments

Subjective assessments create the potential for variability in administration and scoring that may compromise the integrity of a clinical trial. Cogstate supports all aspects of data quality programs for MS cognitive and motor assessments—rater training and certification, subject eligibility review, central monitoring—with proven methodologies and leading technologies that drive endpoint reliability. Studies also benefit from our global network of Local Expert Advisors (LEADs) who are highly trained clinical and scientific experts that provide assessment support in 40+ languages.

Support Electronic Deployment of All Assessments via eCOA Systems

Cogstate partners with industry leading eCOA providers to deliver enhanced tablet-based scales and web-based eSource solutions, combining a user-friendly interface with a secure and reliable data management platform. Custom edit checks and automated scoring help prevent errors, and same day access to cleaner source data enables risk-based central monitoring by our clinical experts for greater quality assurance.

Wearable Sensors for a Complete Picture of Patient Functioning

Cogstate’s strategic partners at Clario deliver a complete wearable precision motion sensor solution that provides meaningful and functional insights for sponsors and patients through the capture of digital biomarkers. When integrated with Cogstate’s clinical outcome assessments of cognition or Clario’s data capture solutions for cardiac safety, eCOA, digital patient, imaging, or respiratory, digital biomarkers provide a holistic story of how a disease and therapy impacts patient function.

Sample Cogstate Multiple Sclerosis Battery

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by MS: processing speed, attention, verbal and visual learning, working memory, visual motor function and executive function.

Each cognitive test has been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

The tests included are a sample based on indication domains of interest. Final battery recommendations may vary based on study needs.

Cogstate Tests:Detection Test
Identification Test
One Card Learning Test
One Back Test
Two Back Test
International Shopping List Test
Groton Maze Learning Test
Length:Between 5-40 minutes
(depending on the number of tests included in the battery)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

EXPLORE OUR TESTS

Decentralized Clinical Trials

We help bring the trial to the patient

As more clinical trials realize the potential of decentralization, Cogstate digital endpoints are enabling at-home, self-administered assessment and our remote rating services are enabling at-home clinician-administered assessment to drive both enhanced data quality as well as patient enrollment, engagement and retention.

SEE HOW WE CAN SUPPORT YOUR FULLY REMOTE OR HYBRID TRIAL DELIVERY

Multiple Sclerosis Resources

[Webinar]

Digital Technologies for Assessing Patient Functioning in Multiple Sclerosis Clinical Trials

Watch now

[Blog]

Reliable and Valid Cognitive Test Results Obtained from MS Patients Performing Self-Administered Computerized Assessment

Read more

[Brochure]

Multiple Sclerosis Clinical Trial Solutions from Cogstate

Read more

Featured Publications

Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review

Authors: Curtis M Wojcik, Meghan Beier, Kathleen Costello, John DeLuca, Anthony Feinstein, Yael Goverover, Mark Gudesblatt, Michael Jaworski III, Rosalind Kalb, Lori Kostich, Nicholas G LaRocca, Jonathan D Rodgers, Ralph HB Benedict, National MS Society Cognition Work Team

Journal: Multiple Sclerosis: Clinical and Laboratory Research

Year Published: 2019

Background: The proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially. Previous reviews of computerized tests for multiple sclerosis (MS) were primarily qualitative and did not rigorously compare CNADs […]

Brief Computer-Based Information Processing Measures are Linked to White Matter Integrity in Pediatric-Onset Multiple Sclerosis

Authors: Elizabeth Bartlett, Michael Shaw, Colleen Schwarz, Charles Feinberg, Christine DeLorenzo, Lauren B. Krupp, Leigh E. Charvet

Journal: Journal of Neuroimaging

Year Published: 2019

Background and Purpose: Pediatric-onset multiple sclerosis (POMS) is a demyelinating disorder with unique clinical challenges. A brief computer-administered cognitive screening battery measuring processing speed (Cogstate) and the Brief International Cognitive Assessment in MS (BICAMS) detect cognitive […]

Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery

Authors: L De Meijer, D Merlo, O Skibina, E J Grobbee, J Gale, J Haartsen, P Maruff, D Darby, H Butzkueven, A Van der Walt

Journal: Multiple Sclerosis Journal - Experimental Translational and Clinical

Year Published: 2018

Background Cognitive monitoring that can detect short-term change in multiple sclerosis is challenging. Computerized cognitive batteries such as the CogState Brief Battery can rapidly assess commonly affected cognitive domains. Objectives The purpose of this study was […]

Cognitive evolution in natalizumab-treated multiple sclerosis patients

Authors: Francois H Jacques, Brian T Harel, Adrian J Schembri, Chantal Paquette, Brigitte Bilodeau, Pawel Kalinowski, Reshmi Roy

Journal: Multiple Sclerosis Journal - Experimental Translational and Clinical

Year Published: 2017

Background: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. Objectives: […]

Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing

Authors: Leigh E Charvet, Michael Shaw, Ariana Frontario, Dawn Langdon, Lauren B Krupp

Journal: Multiple Sclerosis: Clinical and Laboratory Research

Year Published: 2017

Background: Cognitive impairment is a common and troubling feature of pediatric-onset multiple sclerosis (POMS). Brief cognitive assessment in the outpatient setting can identify and longitudinally monitor cognitive involvement so that early intervention is possible. Objectives: The […]

All Publications

Solutions for Every Stage of Your Study Development

Cogstate’s clinical trial services, coupled with innovative operational approaches, advanced analytics, and scientific consulting, help research teams draw conclusions from study data faster and with more accuracy. Learn how we can support your study:

Scientific Consulting

Learn more

Computerized Cognitive Assessment

Learn more

Rater Training

Learn more

Central Monitoring

Learn more

Scale Management

Learn more

Remote / At-home Testing

Learn more

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch

Cogstate
© 2022 Cogstate Ltd.